|
Paroxysmal nocturnal hemoglobinuria: Review of the patient experience and treatment landscape |
Mar 2024 |
Blood Reviews |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Oral Iptacopan Monotherapy in Paroxysmal Nocturnal Hemoglobinuria |
Mar 2024 |
The New England Journal of Medicine |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
SOHO State of the Art Updates and Next Questions: An Update on Higher Risk Myelodysplastic Syndromes |
Mar 2024 |
Clinical Lymphoma, Myeloma & Leukemia |
Myelodysplastic Syndromes (MDS) |
|
Luspatercept in low-risk myelodysplastic syndromes: a paradigm shift in treatment strategies |
Mar 2024 |
Expert Opinion on Biological Therapy |
Myelodysplastic Syndromes (MDS) |
|
T-cell dysfunctions in myelodysplastic syndromes |
Apr 2024 |
Blood |
Myelodysplastic Syndromes (MDS) |
|
Safety and Efficacy of Pegcetacoplan in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria over 48 Weeks: 307 Open-Label Extension Study |
Apr 2024 |
Advances in Therapy |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Quality of life after immune suppressive therapy in aplastic anemia |
Apr 2024 |
Annals of Hematology |
Aplastic Anemia |
|
Hemolysis events in the Phase 3 PEGASUS study of pegcetacoplan in patients with paroxysmal nocturnal hemoglobinuria |
Apr 2024 |
Blood Advances |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Hypomethylating agents are associated with high rates of hematologic toxicity in patients with secondary myeloid neoplasms developing after acquired aplastic anemia |
Apr 2024 |
Haematologica |
Aplastic Anemia |
|
Treatment of Myelodysplastic Syndromes for Older Patients: Current State of Science, Challenges, and Opportunities |
Apr 2024 |
Current Hematologic Malignancy Reports |
Myelodysplastic Syndromes (MDS) |
